Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703151 | 1.00 | POLB (0.50) | POLBNPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL22610059 | 0.90 | NR4A2 (0.47) | POLBNPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL16703153 | 0.88 | LMNA (0.44) | POLBNPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL4726535 | 0.88 | FFAR1 (0.46) | POLBNPC1RAB9ATDP1L3MBTL1 | |
| SCHEMBL17451407 | 0.85 | FFAR1 (0.42) | SMN1; SMN2L3MBTL1KDM4EFFAR1NR4A2 | |
| SCHEMBL3229701 | 0.80 | POLB (0.75) | POLBNPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL4779408 | 0.80 | FFAR1 (0.48) | POLBNPC1RAB9ATDP1L3MBTL1 | |
| SCHEMBL27555763 | 0.80 | TDP1 (0.56) | POLBNPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL4725923 | 0.78 | NR4A2 (0.57) | NPC1RAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL14967365 | 0.77 | NR4A2 (0.73) | POLBNPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265294-B2 | Compositions and methods for treating epithelial cancer | YALE UNIVERSITY (US) | 2019-04-23 | — | — | US | claimed |
| US-9827222-B2 | Treating or preventing nephrogenic diabetes insipidus | EMORY UNIVERSITY (US) | 2017-11-28 | — | — | US | claimed |
| US-20170281588-A1 | Compositions and Methods for Treating Epithelial Cancer | YALE UNIVERSITY | 2017-10-05 | — | — | US | claimed |
| US-20160367516-A1 | Treating or Preventing Nephrogenic Diabetes Insipidus | EMORY UNIVERSITY (US) | 2016-12-22 | — | — | US | claimed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | claimed |
| US-9162994-B2 | 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer | BETAGENON AB (SE) | 2015-10-20 | — | — | US | claimed |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BETAGENON AB | 2012-07-19 | — | — | US | claimed |
| EP-2451794-A2 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2012-05-16 | — | — | EP | claimed |
| WO-2011004162-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2011-01-13 | — | — | WO | claimed |
| WO-2010086613-A1 | COMPOUNDS USEFUL AS INHIBITORS AS AMPK | BETAGENON AB (SE) | 2010-08-05 | — | — | WO | claimed |
| US-12433858-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | NEPHRODI THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-3618821-B1 | MANAGING NEPHROGENIC DIABETES INSIPIDUS | NEPHRODI THERAPEUTICS INC (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240139127-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | NEPHRODI THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11844770-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | NEPHRODI THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4228754-A1 | METHODS OF MANAGING SIDE EFFECTS OF A VASOPRESSIN RECEPTOR ANTAGONIST THERAPY | Emory University (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BETAGENON AB | 2012-07-19 | — | — | US | disclosed |
| EP-2451794-A2 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004162-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010086613-A1 | COMPOUNDS USEFUL AS INHIBITORS AS AMPK | BETAGENON AB (SE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010073011-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139127-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | SLC5A2, SLC5A1, IAPP | POLB 4733/4885NPC1 2457/4885RAB9A 3969/4885 |
| US-11844770-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | SLC5A2, SLC5A1, IAPP | POLB 4739/4885NPC1 2410/4885RAB9A 3934/4885 |
| US-20170281588-A1 | Compositions and Methods for Treating Epithelial Cancer | PKD1, SLC16A1, FOLR1 | POLB 2590/4885NPC1 3220/4885RAB9A 3593/4885 |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, CCND3, MTNR1A | POLB 1874/4885NPC1 3107/4885RAB9A 1865/4885 |
| US-12433858-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | SLC5A1, SLC5A2, IAPP | POLB 4760/4885NPC1 2289/4885RAB9A 3730/4885 |
| US-10265294-B2 | Compositions and methods for treating epithelial cancer | PKD1, SLC16A1, FOLR1 | POLB 2590/4885NPC1 3220/4885RAB9A 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.